If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Merger Update: Wolseley / Kooltech

16 Jan 2024 14:00

RNS Number : 7472Z
Competition and Markets Authority
16 January 2024

Consultation on undertakings in lieu: Anticipated acquisition by Wolseley UK Limited of Kooltech Limited

The Competition and Markets Authority (CMA) has opened a consultation on undertakings in lieu of reference offered by the Parties to address competition concerns identified by the CMA over the anticipated acquisition of Kooltech Limited (Kooltech) by Wolseley UK Limited (Wolseley) (the Merger).

On 23 November 2023, the CMA announced that it would refer the Merger for an in-depth, Phase 2 investigation unless the Parties offered acceptable undertakings in lieu to address the CMA's concerns.

To address the CMA's concerns, the Parties has offered to divest Kooltech's branch in Aberdeen to an upfront buyer approved by the CMA before the CMA finally accepts the Proposed Undertakings.

On 7 December 2003, the CMA announced that it would look in detail at these offered undertakings in lieu. The CMA has until 6 February 2024 to consider whether to accept the undertakings in lieu, or a modified version of them. As part of this process, the CMA is now consulting publicly on whether the proposal is sufficient to address the competition concerns identified by the CMA.

Before reaching a final decision, the CMA is therefore inviting interested parties to make their views known. The deadline for responses is 30 January 2024.

The consultation on the offered undertakings in lieu and all other information relating to this merger investigation can be found on the dedicated case page on the CMA's website at Wolseley/Kooltech merger inquiry - GOV.UK (www.gov.uk).

In the event of media enquiries please email press@cma.gov.uk.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
MERQELFFZFLLBBF

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Back to RNS